Legato Capital Management LLC Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Legato Capital Management LLC bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, Holdings Channel reports. The firm bought 6,479 shares of the company’s stock, valued at approximately $347,000.

Other large investors have also recently added to or reduced their stakes in the company. Plato Investment Management Ltd boosted its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the period. Avanza Fonder AB bought a new stake in Janux Therapeutics during the fourth quarter worth approximately $139,000. Chicago Capital LLC bought a new stake in Janux Therapeutics during the fourth quarter worth approximately $230,000. Finally, AQR Capital Management LLC bought a new stake in Janux Therapeutics during the second quarter worth approximately $215,000. Institutional investors own 75.39% of the company’s stock.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the transaction, the chief executive officer now owns 257,054 shares of the company’s stock, valued at $13,263,986.40. This represents a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,668 shares of company stock worth $4,872,515 over the last three months. 29.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on JANX shares. BTIG Research increased their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Scotiabank upped their target price on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 4th. Finally, UBS Group started coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and a consensus price target of $89.90.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $36.37 on Friday. The stock has a fifty day moving average price of $48.79 and a two-hundred day moving average price of $48.03. Janux Therapeutics, Inc. has a 52-week low of $8.28 and a 52-week high of $71.71. The firm has a market capitalization of $1.91 billion, a P/E ratio of -31.09 and a beta of 3.16.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.